Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evolution of the cancer epigenome in myeloproliferative neoplasms TGS

ABSTRACT: Targeted sequencing of haematopoietic colonies.

PROVIDER: EGAS00001003863 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Evolution of the cancer epigenome in myeloproliferative neoplasms 2

Project description:Whole genome sequencing and bisulphite sequencing of haematopoietic colonies

| EGAS00001002372 | EGA

Evolution of the cancer epigenome in myeloproliferative neoplasms

Project description:Evolution of the cancer epigenome in myeloproliferative neoplasms.

| EGAS00001001941 | EGA

A humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms

Project description:We performed single cell RNA sequencing to ensure that the engrafted MF cells in NSGS mice retained the molecular properties of the patients cells. ScRNAseq profiles from peripheral blood mononuclear cells (PBMCs) from two independent cord blood and MF patient samples were compared to the engrafted hCD45+ cells from the bone marrow of NSGS mice at 12-weeks post-transplant.

2021-09-09 | GSE160927 | GEO

JAK2V617F Myeloproliferative Neoplasms Support Parallel Evolution of Independent Leukemic Clones

Project description:Myeloproliferative neoplasms (MPNs) are hematological diseases predominantly driven by the JAK2V617F mutation. Progression from chronic-phase MPN to secondary acute myeloid leukemia (sAML) is a severe complication as it dramatically worsens disease prognosis. While sAML transformation is classically linked to MPN clones acquiring additional mutations, the absence of JAK2V617F in sAML cases originating from JAK2-mutant MPNs suggests alternative mechanisms. Utilizing patient samples and in vivo modeling, we establish that sAML clones can emerge independently of JAK2-mutant cells. These leukemic clones undergo positive selection in the pro-inflammatory MPN environment leading to their predominance in the hematopoietic system. Genetic and pharmacological inhibition of IL-12 and TNFa mitigates this competitive advantage. Our data establish a new paradigm and show that disease progression in MPN can arise from parallel acute myeloid leukemia (pAML) clones.

2026-02-24 | GSE308233 | GEO

Aetiology of Myeloproliferative Neoplasms.

Project description: Not available

| S-EPMC7408762 | biostudies-literature

Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?

Project description: Not available

| S-EPMC8954627 | biostudies-literature

Myelodysplastic/myeloproliferative neoplasms

Project description:This SuperSeries is composed of the SubSeries listed below.

2010-06-30 | GSE21991 | GEO

Targeting CHAF1B enhances interferon activity in myeloproliferative neoplasms

Project description:Interferons (IFNs) are cytokines with potent anti-neoplastic properties and significant clinical activity in the treatment of myeloproliferative neoplasms (MPNs). The use of pegylated IFN for the treatment of MPNs has been of particular interest, with several clinical trials establishing clinical responses. Here we demonstrate that chromatin assembly factor 1 subunit B (CHAF1B) is overexpressed in MPN patients. Targeted silencing of CHAF1B enhances transcription of IFN-stimulated genes and promotes IFN-dependent anti-neoplastic effects against MPN patient-derived cells. Our findings suggest that targeting CHAF1B in combination with IFN therapy may offer an avenue for the development of effective combination therapies for the treatment of MPNs.

2023-05-15 | PXD037376 | Pride

Myelodysplastic/myeloproliferative neoplasms

Project description:This SuperSeries is composed of the following subset Series: GSE21948: High Density custom Agilent 44K CGH array analysis of 7q and TET2 region in myelodysplastic/myeloproliferative neoplasms GSE21990: Affymetrix SNP 6.0 array data for myelodysplastic/myeloproliferative neoplasms Refer to individual Series

2010-06-30 | E-GEOD-21991 | biostudies-arrayexpress

A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.

Project description: Not available

| S-EPMC8716669 | biostudies-literature